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Abstract: G protein-coupled receptors (GPCRs) have the propensity to form homo- and 
heterodimers. Dysfunction of these dimers has been associated with multiple diseases, e.g., 
pre-eclampsia, schizophrenia, and depression, among others. Over the past two decades, 
considerable efforts have been made towards the development of screening assays for studying 
these GPCR dimer complexes in living cells. As a first step, a robust in vitro assay in an 
overexpression system is essential to identify and characterize specific GPCR–GPCR interactions, 
followed by methodologies to demonstrate association at endogenous levels and eventually in 
vivo. This review focuses on protein complementation assays (PCAs) which have been utilized to 
study GPCR oligomerization. These approaches are typically fluorescence- and 
luminescence-based, making identification and localization of protein–protein interactions feasible. 
The GPCRs of interest are fused to complementary fluorescent or luminescent fragments that, upon 
GPCR di- or oligomerization, may reconstitute to a functional reporter, of which the activity can be 
measured. Various protein complementation assays have the disadvantage that the interaction 
between the reconstituted split fragments is irreversible, which can lead to false positive read-outs. 
Reversible systems offer several advantages, as they do not only allow to follow the kinetics of 
GPCR–GPCR interactions, but also allow evaluation of receptor complex modulation by ligands 
(either agonists or antagonists). Protein complementation assays may be used for high throughput 
screenings as well, which is highly relevant given the growing interest and effort to identify small 
molecule drugs that could potentially target disease-relevant dimers. In addition to providing an 
overview on how PCAs have allowed to gain better insights into GPCR–GPCR interactions, this 
review also aims at providing practical guidance on how to perform PCA-based assays. 
Keywords: G protein-coupled receptor (GPCR), dimerization; oligomerization; protein 
complementation assay; bimolecular fluorescence complementation (BiFC) assay; bimolecular 
luminescence complementation (BiLC) assay 
 
1. Introduction 
Membrane receptors are the key players in mediating communication between the cell and the 
extracellular space. The G protein-coupled receptor (GPCR) protein family represents one of the 
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largest group of cell membrane signaling proteins in the human genome [1]. Currently, 
approximately 800 members of this superfamily are classified according to the International Union 
of Pharmacology, Committee on Receptor Nomenclature and Classification (NC-IUPHAR). Herein, 
GPCRs are grouped into three classes, namely Class A (rhodopsin-like), Class B (secretin receptor 
family), and Class C (metabotropic glutamate-like) [2]. The remaining GPCRs—fungal mating 
pheromone receptors, cyclic AMP receptors, and frizzled/smoothened—are also included in 
alternative classification systems [3]. 
G protein-coupled receptors are activated by a panel of different triggers, including photons, 
nucleotides, ions, hormones, peptides, chemokines, and others. Notwithstanding the broad 
collection of ligands to activate specific GPCRs, they all share a common structure, namely, an 
N-terminal domain, seven transmembrane α-helices, extra- (ECL1–3) and intracellular loops (ICL1–
3) and a C-terminal domain. Specific domains within these GPCRs show plasticity, since 
conformational changes are clearly distinguishable between their activated and inactive states, as 
observed from the crystal structures [4]. Upon activation, the motile domains, such as the ICL3 and 
the C-terminus, are crucial for interaction with intracellular signaling partners, i.e., G-proteins, 
GPCR kinases (GRKs) and β-arrestins. Given their crucial role in cellular signaling, altered activity 
or deviating expression levels of GPCRs have frequently been correlated with diseases, including 
neurodegenerative disorders, depression, and cancer [5–10]. 
Overall, their abundance, regulation in pathophysiology of diverse disease areas, accessibility 
at the cell surface, and availability of druggable binding sites have made GPCRs the largest drug 
target family. It is, hence, not surprising that 34% of the current FDA-approved drugs on the market 
target GPCRs [11]. Interestingly, virtually all pharmaceutical companies have primarily focused on 
GPCR monomers as a target for drug development. However, the recent knowledge that GPCRs 
form homo-oligomeric or hetero-oligomeric complexes has opened up unexplored avenues in the 
development of new drug therapies (e.g., small ligands, peptides, and bivalent ligands) [12–15]. 
1.1. GPCR Dimerization 
There are approximately 150,000 to 300,000 protein–protein interactions in the human 
interactome [16,17] and constant efforts are ever-expanding this number. This also holds true for the 
interest in GPCR–GPCR interactions, as evidenced by the remarkable rise in publications in this field 
of research, with over 300 reports (Figure 1) covering GPCR multimers during the last 5 years. 
 
Figure 1. Number of publications on G protein-coupled receptor (GPCR) dimer and oligomers from 
1997–2019 (data incomplete for 2019). (Source: NCBI—a search for the terms ‘‘GPCR* AND 
DIMER*’ or ‘GPCR* AND OLIGOMER*’’ in the PubMed database). 
While the traditional view on GPCRs was a “one ligand-one monomeric GPCR unit-one 
signaling protein” model, an emerging body of evidence shows that GPCRs can form homo- or 
hetero-oligomeric complexes. This phenomenon adds an additional layer to the complexity of GPCR 
signaling. Dysfunction of these dimers has been associated with multiple diseases, e.g., 
pre-eclampsia (angiotensin II type 1 and bradykinin receptor B2 heterodimer complexes) [18], 
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schizophrenia (dopamine D2 receptor (D2R) heterocomplexes) [19], depression (serotonin 1A 
receptor 5-HT1A and serotonin 7 receptor 5-HT7 heterocomplexes, galanin receptor type 1 (GalR1), 
type 2 (GalR2), and 5-HT1A heterocomplexes) [20–26]. 
Although the concept of GPCR dimerization has been controversial over the past two decades, 
several sophisticated studies have led scientists to the validation of the GPCR dimerization theory. 
An indisputable and widely accepted example is the obligate dimer of Class C GABA receptors [27]. 
These receptors are obligatory dimers, as GABAB1 is necessary for ligand binding and GABAB2 
ensures efficient cell trafficking and downstream signaling. Both protomers are not functional when 
expressed alone. In addition to obligate GPCR dimers observed in Class C receptors, an increasing 
amount of convincing evidence suggests there is also -transient dimer formation between Class A 
GPCRs [28–30]. Conflicting observations both in favor of and against oligomerization have been 
reviewed by Bouvier and Herbert (2014) [31] and by Lambert and Javitch (2014) [32]. Recent insights 
into Class A GPCR dimerization have shed new light on this concept, i.e., a large-scale comparative 
study of 60 members of the Rhodopsin family revealed that only a small fraction, i.e., 20%, forms 
dimers [33]. The dimer formation of Class A GPCRs seems to have a clustered distribution, and 
furthermore, a striking correlation has been suggested between receptor organization and size of the 
GPCR family. A restricted family size, as for the small Glutamate family, correlates with 
predominantly dimeric behavior. This also seems to be true for the receptors exhibiting less diversity 
like the frizzled GPCRs [33]. 
Besides the fact that Class A GPCRs seem to dimerize to a lesser extent as compared to Class C 
receptors, the dimerization event itself is also much more complicated, i.e., Class A GPCRs often 
seem to interact at multiple interfaces, thus causing a broad impact on functionality [34]. This is 
noted in the case for the muscarinic acetylcholine M1 or M2 dimerization, wherein reports have 
suggested that the sites of contact are transient and could involve multiple regions of the receptor 
[35–37]. For the D2R, this transient dimerization phenomenon has been studied in more detail, with a 
lifetime of 68 ms being assigned to the dimer. This dimer lifetime could be prolonged with a factor of 
approximately 1.5 by agonist addition (i.e., dopamine and quinpirole) [38,39], whereas incubation 
with the antagonist spiperone reduced the level of D2R homodimerization by more than 40% [40], 
indicating a potential role of the dimer in signaling cascades. Dijkman and colleagues introduced the 
“rolling dimer” interface model for the neurotensin receptor 1 homodimer. This concept unites 
earlier seemingly conflicting data since multiple dimer conformations could co-exist that 
interconvert during the dimer lifetime, by rotation of the monomers relative to one another. 
In general, the phenomenon of oligomerization can exert a significant impact on receptor–
ligand binding, downstream signaling, crosstalk, internalization, and trafficking. For instance, the 
interaction of D2R with dopamine D3 receptor (D3R) results in a higher potency of certain 
anti-parkinsonian agents, like pramipexole, compared to their monomers [28]. Furthermore, 
selective stimulation of D1R or D2R or both by the neurotransmitter dopamine triggered 
co-internalization of the D1R–D2R heterodimer [29]. 
1.2. Studying GPCR–GPCR Interactions: Biochemical Methods 
In order to target and study GPCR–GPCR interactions, multiple in vitro (and in vivo) 
biochemical and physical, and functional studies have been reported in the literature, which 
described approaches such as co-immunoprecipitation (co-IP), proximity ligation assays (PLA), and 
fluorescence- or bioluminescence-based techniques [41]. 
The presence of multiple protein–protein interactions (PPIs) has been demonstrated by co-IP or 
pull-down assays [42–44]. On a non-reducing SDS-PAGE (sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis), it has been reported that GPCRs often migrate in a way that corresponds to 
twice their molecular weight. Co-IP of endogenous GPCRs entirely relies on the selectivity of the 
antibodies used. Furthermore, this technique necessitates the disruption of biological samples and 
the solubilization of membrane proteins and generally provides no information about the physical 
interaction. 
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On the other hand, fluorescence- or bioluminescence-based energy transfer techniques can be 
applied in living cells, thereby overcoming some of the limitations of the classical biophysical 
techniques. For GPCR dimerization, this has been reviewed by Ciruela et al. (2010) [45]. Fluorescence 
and bioluminescence resonance energy transfer (FRET and BRET) involve the non-radiative energy 
transfer between a donor and acceptor, which allows the examination of PPIs in their native cell 
context by monitoring emissions from the acceptor species. Fluorescence resonance energy transfer 
microscopy offers the advantage that it allows visualization of the interaction inside living cells. 
Bioluminescence resonance energy transfer avoids some of the troubleshooting involved with FRET 
such as photobleaching, spectral bleed-through, etc., but does not provide spatial information on the 
interaction. Below, we will focus primarily on recent advances in yet another biochemical method, 
namely, bioluminescence and fluorescence-based complementation techniques that have been 
applied to study GPCR–GPCR interactions. 
1.3. Protein Complementation Assays 
Protein complementation assays (PCAs), also referred to as split systems, have been 
implemented over the past 2 decades to study PPIs. In these assays, a reporter protein with 
enzymatic or fluorescent properties is engineered or “split” into non-active or non-fluorescent 
fragments. These moieties are fused to potential interacting proteins. Upon interaction, the 
fragments will be brought into close proximity and re-assemble spontaneously into a functional 
biosensor. Although these assays do not formally prove direct protein–protein interactions, they do 
suggest co-localization of the GPCRs of interest since PCAs rely on the fusion partners “interacting”. 
Complementation-based assays comprise bimolecular fluorescence and luminescence 
complementation (BiFC/BiLC) as well as β-Lactamase and β-Galactosidase complementation assays. 
Since 1997, several “split” fluorescent and luminescent proteins have been developed, of which the 
most commonly used ones are shown in the timeline in Figure 2. 
 
Figure 2. History of the development of split protein biosensors. Commonly used fluorescent split 
proteins (yellow), luminescent split reporters (grey), and enzymes with colorigenic substrates (blue) 
are shown. 
These assays have the potential to be implemented as screening assays to identify GPCR–GPCR 
interactions, which later on should be confirmed by a variety of complementary approaches, for 
example, Spatial Intensity Distribution Analysis (SpIDA), advanced microscopy techniques, and 
molecular dynamics, among others [35,39,46–49]. A benefit of a robust complementation assay is not 
only its operational simplicity but even more the possibility to test if dimers occur constitutively or 
whether ligands can alter the oligomeric state of GPCRs. Moreover, these cell-based assays lend 
themselves for early-stage drug discovery, since molecules that potentially exert an impact on the 
level of dimerization, whether desired or undesired, can be rapidly identified. In addition, off-target 
effects can be revealed, such as altered receptor expression, localization or cellular signaling. An 
overview of the available PCAs as of today and their characteristics are presented in Table 1. 
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Table 1. Overview of proteins, already implemented in fluorescence- and luminescence-based complementation assays. N/A = not applicable, nd = not determined. 
Reporter Protein Source Species Readout 
Excitation 
Wavelength 
(nm) 
Emission 
Wavelength 
(nm) 
Substrate Cofactor Stability (h) 
Maturation Time  
(t1/2) (min) 
MW 
(kDa) 
VENUS Aequorea victoria Fluorescence 515 528 - N/A - 40 (in vitro) 27 
GFP Aequorea victoria Fluorescence 488 510 - N/A - 53 (in vitro) 27 
mCherry Discosoma  Fluorescence 587 610 - N/A - 
17 + 30 
(S. cerevisiae) 29 
Cerulean Aequorea victoria Fluorescence 433 475 - N/A - nd 27 
Tripartite-Split GFP Aequorea victoria Fluorescence 488 530 - N/A - nd  23  
EYFP Aequorea victoria Fluorescence 514 527 - N/A - 23 (in vitro) 26.4 
ECFP Aequorea macrodactyla Fluorescence 405 485 - N/A - 49 (S. cerevisiae) 26.8 
Citrine Aequorea victoria Fluorescence 516 529 - N/A - nd 27 
mRFP Discosoma striata Fluorescence 584 607 - N/A - <60 25.9 
mKate Discosoma striata Fluorescence 588 635 - N/A - 20 26 
DsRed monomer Discosoma striata Fluorescence 558 583  - N/A - 600 28 
Renilla luciferase Renilla reniformas Luminescence - 480 Coelenterazine N/A 4.5 h (cell) - 36 
Firefly Luciferase Photinus pyralis Luminescence - 550–570 ᴅ-luciferin ATP, O2 4.0 h (cell) - 62 
Gaussia Luciferase Gaussia princeps Luminescence - 485 Coelenterazine N/A 
60 h (cell 
media) 
- 20 
NanoBiT Oplophorus gracilirostris Luminescence - 460 Furimazine N/A 6.0 h (cell) - 19 
β-lactamase  Bacillus licheniformis Luminescence - 492 Nitrocefin N/A nd - 29 
β-Galactosidase Escherichia coli  Fluorescence Reliant on the 
substrate 
Reliant on the 
substrate 
FDG, MUG a.o. Mg2+ 
1.1 h 
(yeast cells) 
- 464 
Click Beetle luciferase Pyrophorus plagiophthalamus Luminescence - - ᴅ-luciferin Mg2+, ATP - - 64 
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Many questions remain unanswered in the field of GPCR di- and oligomerization. Therefore, it 
is a highly warranted first step to fully characterize the in vitro assays featuring robust sensitivity in 
detecting PPIs of interest. This review aims at offering insight into the progress that has been made 
in the field of protein complementation assays to study GPCR dimerization. This progress concerns, 
for example, optimization of complementation assays in stability and light output by a consensus 
sequence driven strategy. Several mutations applied in fluorescent and luminescent 
complementation assays in the field of GPCR dimerization will be discussed throughout the 
following sections of this review, for additional information concerning mutational optimization of 
split reporter genes in general, we refer to the excellent review by Wehr and Rossner [50]. 
2. Fluorescence-Based Complementation Assays 
One of the well-studied PCAs is BiFC, which is based on the structural and functional 
complementation of two non-fluorescent protein fragments brought into close proximity by their 
interacting fusion partners (Figure 3). Upon complementation of the fluorescent protein, the 
fluorescence can be read via a plate-reader, imaged using a fluorescence microscope or even 
analyzed by flow cytometry without the need for any treatment of the cells. 
In 1999, Regan and colleagues reported BiFC for the first time in Escherichia coli (E. coli) by using 
a strategy based on the non-covalent association of the split fragments of green fluorescent protein 
(GFP), fused to two antiparallel leucine zippers [51]. Subsequently, Hu et al. [52] reported on the 
development of a BiFC assay based on the split fragments of yellow fluorescent protein (YFP), 
tagged to two interacting transcription factors in living mammalian cells. Shyu et al. [53] developed 
Venus, one of the brightest fluorescent proteins, for studying PPIs at physiological conditions using 
BiFC. Since then, numerous types of fluorescence complementation-based assays have been 
developed to visualize signaling events involving two or even more interacting proteins, ranging 
from bacteria to mammalian cells. 
A 
 
B Split Cerulean Split Venus 
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Figure 3. Fluorescence-based complementation assay. (A). The principle of the fluorescent 
complementation assay is shown schematically. (B). Split versions of the fluorescent reporters 
Cerulean and Venus are shown in green and red. Purple refers to overlapping sections. (PDB; 
Accession no. 3AKO for Venus; PDB: Accession no. 5OXB for Cerulean). 
2.1. Fluorescent Proteins 
2.1.1. Green Fluorescent Protein (GFP) 
Regan and colleagues used GFP, the first fluorescent protein, for characterizing BiFC by tagging 
the split fragments of GFP, i.e., NGFP and CGFP, split at residue 157–158, to strongly interacting 
antiparallel leucine zippers. The split fragments did not self-assemble in bacteria, whereas upon 
fusion to antiparallel leucine zippers, the fragments could properly fold to form a functional GFP 
protein, and hence, gain fluorescence. A recent study performed by Son and colleagues [54] made 
use of enhanced GFP (EGFP), an improved version of GFP that is brighter and more photostable. 
The EGFP molecule was split to yield N-EGFP (1–158) and C-EGFP (159–238), respectively. These 
split parts were fused to α-factor receptor (Ste2p), to study homodimerization in S. cerevisiae. Both 
full length and C-terminally truncated forms of the receptors led to fluorescence, indicating 
dimerization. 
A recent advance in BiFC based on GFP is Tripartite GFP, introduced by Cabantous et al. [55] in 
2013 in an attempt to cope with the problem of poor folding and self-assembly seen with split GFP. 
Tripartite GFP is based on the tripartite association of two twenty amino-acid residue fragments of 
GFP, coined as GFP 10 and GFP 11, that can be fused to the proteins under investigation, and the 
complementary GFP 1–9 detector. Upon interaction between the protein partners, GFP 10 and GFP 
11 associate with GFP 1–9 to form the functional GFP molecule. This system was initially 
characterized in E. coli and in mammalian cells, where the rapamycin induced association of FRB 
(FKBP-rapamycin binding domain of mTOR) and FKBP12 (FK506- and rapamycin-binding protein) 
was studied. This system has extensively been exploited for the validation of multiple reporter 
systems. Although use of this Tripartite GFP system has not been reported for studying GPCR 
dimerization, it could be an advantageous platform to be used over the conventional split GFP. 
2.1.2. Yellow Fluorescent Protein (YFP) Variants 
In 2001, Nagai et al. [56] first demonstrated the use of the yellow fluorescent protein (YFP) in 
BiFC, wherein they used a variant of YFP to study the effect of Ca2+ on PPI in living cells. Shortly 
after, Griesbeck and colleagues [52,57] tried several permutations and combinations of split regions 
in EYFP (S65G, S72A, T203Y) to improve the fluorescence signal along with minimal self-assembly of 
the split fragments. Several variants of YFP have been developed such as Citrine (a variant having a 
Q69M mutation) and Venus (a variant carrying a F46L mutation), that folds even at a physiological 
temperature of 37 °C [58]. This led to the usage of these fluorescent protein fragments to study 
GPCR–GPCR interactions. 
Vidi et al. (2008) [59,60] used split fragments of Venus fused to the adenosine A2A receptor (A2A) 
to address the question about A2A oligomerization in the CAD neuronal cell line. Co-expression of 
A2A-VN and A2A-VC in these cells, as well as in HEK293 cells, resulted in fluorescence, indicating A2A 
dimerization, in contrast to negative controls wherein cells transfected with 
A2A-VN/D1R-VC/M4R-VC did not show any fluorescence, pointing at the specificity of the 
interaction. 
Similarly, Kilpatrick et al. (2014) [61] assessed dimerization of a receptor for NPY, 
Neuropeptide Y Y1/Y5. This neuropeptide is a widely expressed modulator of the central nervous 
system, mainly known for its role in the regulation of appetite upon its release from hypothalamic 
arcuate neurons. The receptors, tagged with split YFP, showed heterodimerization and the 
irreversible nature of these fragment tags also helped to elucidate the cellular localization of these 
dimers. Evaluation of the effect of ligands on the internalization of dimers, as opposed to individual 
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protomers, demonstrated that Y1/Y5 receptor dimers displayed altered ligand pharmacology, 
indicative of allosteric interaction. 
Przybyla and Watts [62] in 2010 used Venus-based BiFC to demonstrate heterodimerization 
between the cannabinoid receptor 1 (CB1) and the dopamine D2Long receptor (D2LR) in CAD cells, 
wherein CB1 and D2LR receptors were fused at their C-terminus to VN and the C-terminal fragment 
of Cerulean (CC), respectively (see Section 2.2.1). 
Ang et al. [63] in 2018 assessed homo- and heterodimerization of free fatty acid receptors, 
GPCRs that are expressed on mammalian cells to sense the short-chain fatty acids derived from the 
microbiota. To study dimerization, HEK293T cells were transfected with VN- or VC-tagged (free 
fatty acid receptor 2/3) FFAR2/3 receptor. Homodimerization of FFAR3 and FFAR2, as well as 
heterodimerization between FFAR2-VN and FFAR3-VC were observed, as compared to negative 
control FFAR2/3 tagged to VN or VC plus P2RY1-VN or P2RY1-VC (for heterodimerization) and 
P2RY1-VN plus P2RY1-VC (for homodimerization). 
Xue et al. [64] in 2018 used a BiFC assay based on split Venus to detect heterodimerization 
between growth hormone secretagogue receptor 1α (GHSR1a) and Orexin 1 receptor (OX1R). 
Recently, Navarro et al. [65] (2018) used interfering peptides corresponding to regions in TM1–7 
domain for A2A and TM5–7 domain for A1, each fused to TAT peptides, to disrupt the interaction 
between the A1–A2A heteromer. They therefore expressed receptors tagged with split fragments of 
YFP (nYFP and cYFP) in HEK293T cells. In the absence of the TM peptides, fluorescence 
complementation was detected for A2A-nYFP and A2A-cYFP in the presence of untagged A1, 
suggesting homodimerization of A2A. The interaction sites were mapped to TM4 and 5 of A2A with 
the help of interfering peptides. In the same way, a fluorescence signal corresponding to the 
heterodimer (A1-nYFP and A2A-cYFP) was also detected. Upon addition of TM peptides 
corresponding to regions 5/6, a reduction in fluorescence was observed, suggesting the involvement 
of these regions in the formation of the heterodimer. In the same year (2018), BiFC using split 
fragments of YFP was utilized by Hinz et al. [66] for studying homodimerization between A2A and 
heterodimerization with A2B receptor. For this purpose, CHO cells were transfected with a constant 
amount of A2A-NYFP and increasing amounts of HA-A2A-CYFP and a strong fluorescence signal was 
observed, indicative of the A2A-A2A homodimer. For the purpose of studying A2B-A2A 
heterodimerization, the GPCRs were tagged with NYFP and CYFP, respectively. CHO cells 
transfected with constant amounts of A2B-NYFP and increasing amounts of HA-A2A-CYFP showed 
significantly higher fluorescence when compared to the negative control comprising of 
GABAB2-NYFP and increasing amounts of HA-A2A-CYFP. 
An interesting study was performed by Song et al. [67] in 2019, where a homo-molecular 
fluorescence complementation (homo-FC) probe was designed by splitting a single fluorescent 
protein (superfolder GFP, sfGFP) into two fragments and linking the C-terminal fragment (strands 
8–11) with a short linker N-terminally to the N-terminal fragment (strands 1–7). This “flopped 
fusion” construct, which does not show intramolecular self-complementation, was used to tag the β2 
adrenergic receptor (β2-AR), to study its homodimerization. A fluorescent signal was generated by 
complementation of strands 1–7 of one “flopped” sfGFP molecule, fused to one β2-AR, with strands 
8–11 of another “flopped” sGFP molecule, fused to a second β2-AR. The advantage of this approach 
lies in the fact that only one receptor construct needs to be generated, to allow the assessment of 
homodimerization. 
2.1.3. Cyan Fluorescent Protein (CFP) 
Apart from using the aforementioned split Venus, Vidi et al. [59,68] also used split fragments of 
Cerulean to show that A2A homodimerizes in CAD cells (see Section 2.2.1). The same fluorescent 
protein fragments were also used in 2010 by Przybyla and Watts [62] to illustrate the 
homodimerization of D2LR. 
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2.1.4. Red, Far-Red and Near-Infrared Fluorescent Proteins 
Red fluorescent proteins encompass a couple of fluorescent proteins that emit in the red region 
of the visible spectrum. They have evolved through time to overcome issues such as slow 
maturation or the tendency to oligomerize (as exhibited by Discosoma Red (DsRed)) [69]. Red 
variants such as monomer red fluorescent protein 1 (mRFP1) are not appropriate for BiFC due to 
their low extinction coefficient, quantum yield, and low photostability, despite faster maturation 
than DsRed and better tissue penetration. Although several variants of RFP have been used for 
FRET, BiFC assays with the split parts have not been reported for demonstrating GPCR–GPCR 
interactions. 
For imaging deep tissues in animals, fluorescent proteins with emission in the far-red region of 
the spectrum are chosen. RFP, mcherry and DsRed, have limited application in BiFC due to the 
requirement of low temperatures for their maturation [70,71]. This led to the development of mKate, 
a far-red, monomeric form of Katushka fluorescent protein, that matures faster and is photostable 
[72]. BiFC based on split fragments of mKate fused to transcription factors was successfully applied 
in COS-7 cells [73], but has not been applied yet for studying GPCR oligomerization. 
2.2. BiFC Assays 
2.2.1. MBiFC 
Multicolor BiFC (MBiFC) has gained a lot of attention in recent years as it essentially gives the 
freedom to explore multiple protein–protein interactions inside the same living cell [74]. It has been 
studied with split parts of Venus and Cerulean, wherein the C terminal part of Cerulean is tagged to 
protein A (CC), the N-terminal part of Venus is tagged to protein B (VN), and finally, the N-terminal 
fragment of Cerulean is fused to protein C (CN). The C-terminal fragment of Cerulean (CC), 
comprising residues 155–238 (C155), can functionally complement with the N-terminal fragment of 
VN and CN, comprising residues 1–172 (N173), to produce a Venus (VN+CC) signal or Cerulean 
(CN+CC) signal. Since these parts are non-fluorescent per se, simple employment of different 
excitation and emission wavelengths allows to study simultaneously the interaction between A–B 
and A–C within the same cell [59,75,76]. 
Multicolor BiFC has aided in the understanding of GPCR oligomerization amongst all its other 
applications. Vidi et al. [59] (2008) used MBiFC to visualize the hetero- and homodimerization 
capacity of A2A in the CAD neuronal cell line. To this end, D2LR-VN was co-transfected with A2A-CN 
and A2A-CC in CAD cells. The detection of Venus (D2LR-VN/A2A-CC) and Cerulean (A2A-CN/A2A-CC) 
fluorescence signals revealed the presence of the A2A–D2LR heteromer and A2A homomer, 
respectively. In addition, fluorescence microscopy also revealed that the dimers were localized at the 
plasma membrane as well as in intracellular compartments. 
Przybyla and Watts [62] in 2010 showed oligomerization of CB1 and D2LR. To achieve this, they 
used CAD cells that expressed CB1-VN and D2LR fused to the split fragments of Cerulean (D2LR-CN, 
D2LR-CC) and these cells were imaged using fluorescence microscopy. The heterodimers in the cell 
formed by CB1-VN–D2LR-CC produced a Venus signal that was mainly localized in the intracellular 
compartment, whereas the homodimers of D2LR produced a Cerulean signal that was localized both 
in the intracellular compartment and on the plasma membrane. 
2.2.2. BiFC-RET 
The fluorescent proteins used in BiFC could also be coupled to FRET or BRET to study GPCR 
oligomerization, e.g., functionally complemented YFP could act as a FRET/BRET acceptor. 
BiFC-BRET [77] employs the energy transfer between GPCR-A fused to a luciferase and the 
complemented fragments of YFP that are fused to GPCR-B and GPCR-C that are as close as 10 nm 
apart, indicating a trivalent complex of GPCRs. 
Navarro et al. [78] in 2008 used BiFC-BRET to demonstrate the interaction between D2R, A2A, 
and CB1 receptors in HEK cells. The split fragments of YFP fused to CB1 and A2A acted as the 
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acceptor fluorophore in BRET, and Renilla luciferase (RLuc) fused to D2R (D2R-RLuc) acting as the 
donor. 
BiFC-FRET [79] is similar, offering the additional benefit that the complex can be visualized 
within the cell. BiFC-FRET was used to understand the existence of higher order oligomers in the 
case of A2A by using fusion constructs with Cerulean and split parts of Venus. Prior to this, to test if 
the system could record FRET, A2A dimerization was tested by fusing A2A to Cerulean and Venus. 
Based on this, CAD neuronal cells were co-transfected with A2A-Cerulean and A2A fused to split 
parts of Venus. FRET signals were detected, suggesting the existence of A2A oligomers, as opposed to 
a negative control wherein cells transfected with M4 as the acceptor only showed very low FRET 
[60]. 
In 2017, Bagher et al. [80] combined BRET with BiFC which forms the basis of “sequential 
resonance energy transfer 2” (SRET2). Herein, the donor for BRET was the Renilla luciferase (RLuc) 
fused to D2LR (D2LR-RLuc), which upon addition of the substrate coelenterazine 400a, excited the 
acceptor GFP2 fused to D2LR (D2LR-GFP2), thereby confirming the homodimerization of D2LR. 
Sequentially, the GFP2 acted as FRET donor for the CB1-VN/CB1-VC homodimer, thus providing 
evidence for heterotetramerization. With increasing concentrations of CB1-VN/CB1-VC, there was a 
hyperbolic increase in net SRET2, as opposed to negative control cells that were transfected with 
D2LR-RLuc and mGLuR6-GFP2 and increasing concentrations of CB1-VN/CB1-VC, confirming that 
the homodimers of D2LR and CB1 associate to form oligomers. 
2.3. Ligand-Dependent Modulation of Dimerization 
The level of GPCR dimer formation could possibly be altered by ligands interacting with the 
receptor(s). The potential of split-protein sensors to monitor the dynamic changes in dimerization, 
provoked by chemical inducers or inhibitors, was demonstrated using the rapamycin-dependent 
FKBP/FRB Chemically Induced Dimerization (CID) system[81]. The first demonstration for the use 
of MBiFC to monitor drug-modulated GPCR oligomerization was published by Vidi et al. [59] in 
2008  for the A2A–D2R interaction. Stimulation of D2R with the D2R agonist quinpirole led to 
internalization of D2R homodimers as well as of A2A−D2R oligomers, which was blocked by the D2R 
antagonist, sulpiride [59]. Furthermore, treatment with quinpirole decreased the formation of 
A2A−D2R heterodimers, as compared to A2A homodimers. Also, treatment with 
5-N-methylcarboxamidoadenosine (MECA), an agonist for the adenosine receptor, increased the 
proportion of A2A/D2LR heterodimers, as compared to homodimers of A2A, while treatment with its 
antagonist (CGS15943) had no effect on BiFC. Interestingly, these drug-induced alterations on the 
formation of oligomers could not be supported by changes in the receptor density. 
As discussed above, Przybyla and Watts [62] demonstrated heterodimerization of CB1−D2LR 
using MBiFC. Also, the influence of ligands on the balance between hetero- and homodimers was 
analyzed. Quinpirole and CP55,940 shifted the balance towards the formation of CB1−D2LR 
heterodimers, as opposed to D2LR−D2LR homodimers. The D2R antagonist sulpiride favored D2LR 
homodimerization. Consequently, it was shown that sustained treatment with quinpirole influenced 
the expression of D2LR, which in turn might affect the dimerization status inside the cell as: 
D2LR−CB1 > D2LR−D2LR > A2A−D2LR. In a similar way, studies also indicated that a CB1 antagonist 
(1-(7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo 
(1,5-a)-(1,3,5)triazin-4-yl)-3-ethylaminoazetidine-3-carboxylic acid amide benzenesulfonate) could 
have a potential therapeutic role in Parkinsonism by enhancing the activity of L-DOPA [82]. 
In 2018, Navarro et al. [65] evaluated if activation of A1 or A2A alone or by a combination of 
agonists could modulate the TM interface of the heteromer formed by A2A-nYFP and A1-cYFP. 
Selective agonists for A1, N6-cyclopentyladenosine (CPA), and A2A, 
4-(2-((6-Amino-9-(N-ethyl-β-D-ribofuranuronamidosyl)-9H-purin-2-yl) amino) ethyl) 
benzenepropanoic acid (CGS-21680), were used alone or in combination. None of the agonists, either 
used in combination or alone, could modify the TM interface of the A1−A2A heterodimer. 
Various ligands were tested for their capacity to affect β2AR oligomerization by Song et al. [67] 
in 2019. A panel of compounds consisting of five agonists, two antagonists, and two inverse agonists 
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were screened using the abovementioned homo-FC assay. They observed that agonists induced 
oligomerization, while inverse agonists reduced the signals, and a combination of both also resulted 
in reduced intensity of signal, thus confirming the same. 
3. Luminescence-Based Complementation Assays 
Luciferases, which have seen an expansive growth in use as reporter proteins in biological 
research, are attractive due to the high signal-to-background ratio associated with their usage, as no 
excitation light is required to generate a signal [83]. Similar to fluorescent proteins, these enzymes 
can also be used in applications where the luminescent protein itself is split into two fragments, 
which are conjugated to proteins of interest (Figure 4). Several luminescent proteins have served this 
purpose, with Firefly luciferase (FLuc) [84,85] and Renilla luciferase (Rluc) [86,87] being the two most 
commonly used bioluminescent proteins. However, many other novel luciferases have also been 
developed with favorable characteristics in terms of stability, substrate requirement, brightness, and 
emission spectrum, e.g., Gaussia princeps luciferase (GLuc) [88] and NanoLuciferase [89–91]. All 
mentioned split-protein reporters were initially validated using the aforementioned FKBP/FRB CID 
system [84,88,92–94]. 
A 
 
B Split Firefly Luciferase Split Renilla Luciferase NanoBiT® 
   
Figure 4. Luminescence-based protein complementation assay. (A) The principle of the luminescent 
complementation assay is shown schematically. (B) Split versions of the luminescent reporters 
Firefly, Renilla, and Nanoluciferase are shown in blue and red. Purple refers to overlapping sections. 
Split luminescent biosensors are depicted in proportion to their size (Fluc: 62 kDa, Rluc: 36 kDa, and 
NanoBiT®: 19 kDa) (PDB Accession no. 1LCI for Firefly luciferase, PDB Accession no. 2PSD for 
Renilla luciferase) (NanoBiT®: source Promega). 
3.1. Renilla/Firefly Luciferase 
FLuc is the least optimal reporter for employment as a bioluminescent tag, due to its size (±60 
kDa) and its dependence on ATP, molecular oxygen, and magnesium for activity. Luciferases that 
use coelenterazine as a substrate, such as the luciferase from the sea pansy Renilla reniformis RLuc 
[95,96], have an advantage over FLuc in that they are not ATP dependent and only require the 
presence of molecular oxygen for the enzyme-catalyzed conversion of a substrate to a luminescent 
reaction product. As the bioluminescent activity of formerly used non-truncated luciferases is a 
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limiting factor to permit their application in high throughput screenings, specific mutations of 
certain luciferases, like in RLuc, were selected using a consensus sequence-driven strategy and 
screened for their ability to confer stability in activity as well as for their light output [97].  
For GPCR dimerization purposes, the split-luciferase reporter approaches have not been 
applied to the same extent as their fluorescence counterparts. Nevertheless, these reporter systems 
also allow the rapid detection of macromolecular GPCR–GPCR interactions. For instance, the split 
FLuc methodology was used in cell culture models as well as in tumor xenograft models of breast 
cancer (see Section 8) to measure changes in chemokine receptor CXCR4 (and CXCR7) 
homodimerization in response to pharmacological agents [98]. Likewise, the CXCR4 homodimer has 
also been demonstrated with a split RLuc assay [99]. For this Renilla luciferase complementation 
assay, RlucII was implemented, which is derived from RLuc, wherein two mutations (C124A and 
M185V) were introduced to make it brighter. 
For studying dopamine D2R oligomers, an alternative RLuc construct was implemented, 
namely, Rluc8 [100]. Owing to eight favorable mutations, this RLuc8 has a 4-fold improved light 
output, compared with the parental enzyme [97]. More recently, the same complementation assay 
was also used by Casado–Anguera et al. [101] (2016) to demonstrate the existence of a 
therapeutically relevant GPCR dimer, namely, the A2a−D2R dimer. This dimer and its inter-protomer 
allosteric mechanisms have been proposed as a new model that could contribute to our knowledge 
concerning drug dosage for the treatment of Parkinson’s disease. 
3.2. NanoLuciferase 
One of the most recent and undoubtedly the most optimized luminescent PCA so far is 
“NanoLuciferase Binary Technology” or the NanoBiT® system, developed by Promega. The assay is 
based on complementation of the split fragments of NanoLuciferase or NanoLuc. This engineered 
luciferase reporter is a small (19 kDa), ATP-independent luminescent protein, originating from a 
luminous deep-sea shrimp, Oplophorus gracilirostris [102]. In combination with the development of a 
novel cell-permeable imidazopyrazinone substrate, furimazine, this bioluminescence system 
generates a glow-type luminescent signal that is over 150-fold greater compared to that of the former 
Renilla and Firefly luciferases. NanoLuc exhibits high physical stability, in a wide range of 
environmental conditions such as temperature, pH, urea, and ionic strength [103]. As opposed to 
luminescent protein fragments described earlier, the NanoBiT® subunits do not consist of two 
fragments similar in size but correspond to a small 1.3 kDa subunit (Small BiT; SmBiT) and an 18 
kDa subunit (Large BiT; LgBiT). Both subunits have been thoroughly characterized and have a low 
affinity (KD = 190 µM) for one another, thus providing the ability to follow kinetics of PPIs. 
Although the NanoBiT® PCA has only recently been developed [92], its broad applicability has 
proven successful in numerous research fields. NanoBiT® has, for instance, been applied to develop 
bio-assays based on the recruitment of β-arrestins [104–110] and G-proteins [111] for the detection or 
activity profiling of certain compounds or to elucidate the molecular interaction between the 
transducer and a GPCR. For GPCR dimerization purposes, NanoBiT® has been implemented to 
detect ligand-dependent modulation of D2LR−D2LR homodimers [40,112]. The methodology has also 
been used to perform live-cell monitoring of the dynamics of the interaction between the 
Melanocortin 4 receptor (MC4R), and the Melanocortin 2 receptor accessory protein 2 (MRAP2), as 
well as of MC4R homodimerization [113]. 
The NanoBiT® system has been further optimized into a tri-part protein fragment 
complementation assay by two independent groups [114,115]. For this purpose, the LgBiT was 
dissected into a smaller C-terminal part of 11 amino acids (LcBiT) and an N-terminal derivative 
(LnBiT), serving as a “detector” protein of 16.5 kDa, similar to the Tripartite GFP mentioned in 
Section 2.1.1. Initially, this assay was designed to facilitate the purification of fusion proteins to 
procure significant quantities and to avoid the lapse of detection of the PPI of interest due to the 
steric hindrance of LgBiT, due to its higher molecular weight. In addition, another novel 
split-luciferase reporter based on NanoBiT® was developed that implements GFP- and 
mCherry-recognizing nanobodies fused to LgBiT and SmBiT [116]. Using this experimental set-up, 
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GFP- or mCherry-tagged dimers or higher order oligomers can be detected. As fluorescently tagged 
proteins are already often in use, this luminescent PCA can be directly used and consequently 
bypasses the tedious protein re-cloning to explore the different possible configurations for setting up 
a PCA (also see Section 6). Furthermore, due to the strong affinity of the GFP- and 
mCherry-recognizing nanobodies, a low limit of detection of PPIs or protein aggregations, from 
micromolar up to low nanomolar, can be achieved. 
3.3. BiLC-RET 
The application of BiLC has already shown its efficiency in combination with a BRET assay, 
allowing to detect ternary protein complexes. Sahlholm et al. [117] (2018) demonstrated, by 
combining BiLC of D2R−A2a heterodimers with a YFP-tagged β-arrestin, a BRET signal could be 
obtained. Furthermore, it was postulated that D2R agonists quinpirole or UNC9994 require the 
formation of D2R−A2aR heterodimers, to promote β-arrestin2 recruitment. 
4. Combinatorial Assays: BiFC and BiLC 
For the detection of higher order oligomerization of GPCRs, a combinatorial assay with both 
BiFC and BiLC can be implemented (Table 2). Rebois et al. [77] (2008) introduced the concept of 
detection of a tetravalent complex using a combination of BiFC and BiLC, wherein four β2ARs were 
fused to split parts of Venus or GLuc and the homodimerized β2AR-GLuc acted as the donor for the 
homodimerized β2AR-Venus acceptor, the presence of a BRET signal indicating the presence of the 
tetramer. In the same year (2008), Guo and colleagues [100] showed the existence of a D2R 
homo-oligomer, using the same technique. 
A complemented donor–acceptor resonance energy transfer (CODA-RET) assay showed that 
the A2A−D2R dimer not only forms dimers but can also assemble to form a heterotetramer, composed 
of two receptor homodimers [118,101]. For this experimental setup, a complemented YFP was 
implemented and combined with Rluc8. 
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Table 2. Combinatorial assays with BiFC and BiLC for GPCR oligomerization purposes. 
GPCR Dimer Oligomeric Type PCA Type Split 
Biosensor 
Fragments Negative Control Cell-Type Year  Ref. 
CXCR4−CXCR4/CC2 Hetero-oligomer with CC2, 
homotetramer 
BiLC and BiFC RLucII, vYFP 
RLucII: 1–330, 331–936 
vYFP: 1–465, 466–720 
D2R HEK293 2014 [99] 
A2a−D2R heterotetramer BiLC and BiFC RLuc8, YFP RLuc8: 1–229, 230–311 
YFP: 1–155, 156–238 
A1R, D1R HEK293 2015/2016 [118,101] 
D2SR−D2SR Homo-oligomer BiLC and BiFC RLuc8, 
mVenus 
RLuc8: 1–229, 230–311 
mVenus: 1–155, 156–240 
CD8, TSHr HEK293T 2008 [100] 
β2AR−β2AR homotetramer BiLC and BiFC GLuc, Venus GLuc: 1–63, 64–185 GLucN, VN, VC HEK293 2008 [77] 
 
Int. J. Mol. Sci. 2019, 20, 2958 15 of 35 
 
5. Comparison of Split Protein Approaches 
Protein complementation techniques have shown their applicability in many fields to unravel 
PPIs. However, every technique has its advantages and limitations, as summarized in Table 3 for 
BiFC and BiLC. 
5.1. Advantages of PCA 
A key advantage of BiFC and BiLC lies in the fact that complementation assays offer a robust 
and straightforward approach to evaluate PPIs in living cells. Consequently, their applicability in 
high-throughput experiments is a valuable quality. The development of MBiFC, BiFC-RET, or 
CODA-RET has made the detection of multiple protein–protein interactions feasible, such as GPCR 
oligomers, without the need for cell lysis or fixation. Due to the simplicity of performing these 
assays, they can be used as a screening platform for drugs [59]. When used with a plate reader, BiFC 
and BiLC also offer quantitative and rapid results on relatively large cell populations. 
The most valuable aspect of BiLC is that kinetic measurements can be performed due to its 
sensitivity and the limited propensity of self-association events, at least for certain BiLC reporters 
(e.g., NanoBiT®). For the purpose of studying GPCR dimerization, the NanoBiT® assay has been 
compared to related bioluminescence and fluorescence PCAs, including split Venus and RLuc [112]. 
As a benchmark, the generally accepted D2R−D2R dimer was compared in the different PCAs. The 
NanoBiT® assay presented the best signal-to-noise ratio and was considered the most optimal 
candidate assay for targeting GPCR dimers. In addition, this method can also be implemented to 
analyze the kinetics of ligand-dependent modulation of dimerization, broadening its application 
potential [40]. Even high-throughput screenings can be performed, which is highly relevant, given 
the growing interest and effort to identify small molecule drugs that can target disease-relevant 
dimers (or even selectively alter GPCR dimer function). Moreover, BiLC has also proven its 
applicability in an in vivo setup [85,87]. 
On the other hand, BiFC has the capacity to visualize and localize the interaction, also offering 
insight into potential protein aggregation artefacts inside the cell. BiFC does not require any 
exogenous stains or substrate. Thus, depending on the intrinsic fluorescence, it allows the direct 
measurement of the interaction between proteins. 
5.2. Limitations of PCA 
BiFC and BiLC also come with their own set of drawbacks. First of all, both techniques require 
the fusion of the target proteins with split fragments of a fluorescent or luminescent protein, which 
could affect the original proteins’ interaction dynamics. Moreover, the amount of proteins expressed 
by the cell may potentially cause false positive readouts. Therefore, a good set of negative controls is 
obligatory (see Section 6.3). In addition, one should bear in mind that these techniques, though 
indicating the close proximity of the proteins being studied, are not an actual assessment of the 
physical contact between these proteins. 
BiFC needs a longer maturation time, has an irreversible nature of complementation, shows a 
high degree of self-assembly of the split fragments of the fluorescent protein, and requires molecular 
oxygen for the maturation of the fluorophore, thereby making it unsuitable for obligate anaerobes. 
Since maturation is a time-dependent process, the data procured from BiFC are not in real time. The 
irreversibility of the technique also makes it more difficult to study the dynamics of interactions 
inside the cell and the influence of drugs on the interaction. Despite these limitations, BiFC is still the 
only protein complementation technique that gives information about the location of PPIs in living 
cells. For BiLC, its limitations are the need of a substrate and the rather limited possibility to detect 
the localization of the interaction. 
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Table 3. Advantages and disadvantages of BiFC and BiLC techniques. 
BiFC 
Advantages Disadvantages 
Straightforward technique Need for tagged proteins (GPCRs) 
High-throughput experiments Autofluorescence 
Imaging microscopy: localization of the interaction Photobleaching 
Study intact cells 
Measuring dynamics: limited (maturation time) 
Not applicable for studying inhibition of interactions 
BiLC 
Advantages Disadvantages 
Straightforward technique Need for tagged proteins (GPCRs) 
High-throughput experiments Requires a substrate 
Kinetic measurements Detection of localization: limited 
Study intact cells  
In vivo application  
6. Guidelines to Perform Accurate PCA-Based Assays 
A potential but inherent drawback of PCA-based assays is the requirement to fuse fragments 
derived from fluorescent or luminescent proteins to the GPCR, which inherently may alter the 
GPCR’s function or cellular localization. Therefore, a list of recommendations for proper 
implementation of PCA-based assays can be put forward: 1) examine all possible combinations of 
fusion proteins; 2) verify the functionality and localization of the fused proteins; 3) include proper 
controls, i.e., non-interacting partners, to control for self-assembly; 4) include a normalization 
reporter, to allow compensation for differences in transfection efficiencies; 5) preferentially transfect 
an amount of DNA near to endogenous expression levels of GPCRs, to avoid false positives due to 
the random collisions or potentially generate stable cell lines; and 6) follow the kinetics of the GPCR 
interaction (Figure 5). 
 
Figure 5. A guideline for the set-up of an optimized PCA. 
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6.1. Possible Fusions 
The development of PCAs requires multiple rounds of cloning, as one needs to design the most 
optimal “split” system for each GPCR of interest. Several configurations should be explored, being 
(i) different reporter systems, (ii) (N- or) C-terminally tagged proteins, and (iii) diverse linkers (i.e., 
length and composition). While this is a time-consuming step, having a certain workload, it is of 
paramount importance for the development of a robust, sensitive, and successful complementation 
assay. 
6.1.1. Selection of the Reporter System 
A broad variety of fluorescent and luminescent split reporter fragments is available to unravel 
PPIs. For studying GPCR dimerization, different split reporter systems might be advised, depending 
on the characteristics of the GPCR dimer of interest (if known). For obligate GPCR dimers, the rules 
could be less stringent for the choice of the reporter system to be used, whereas for transient GPCR 
dimers, a dynamic reporter assay with kinetic measurements close to real-time is required. When 
BiFC is preferred, the truncated YFP fragments YN155 and YC155 are recommended, due to the high 
signal-to-noise ratio [119]. Venus, a brighter version of GFP, split at 155 or 173, is also commonly 
used for studying protein interactions. The benefit of using Venus fragments over YFP is that the 
complementation can be read at 37 °C, thus avoiding the incubation at 30 °C which is necessary 
when dealing with split-YFP. 
When BiLC is preferred, the NanoBiT® system offers advantages in flexibility and in the low 
affinity of the SmBiT–LgBiT fragments for each other, so dynamic interactions can be monitored in 
living cells in real time [92]. 
6.1.2. (N- or) C-Terminally Tagged GPCRs 
The site at which the tag is fused to a GPCR plays an important role in the functionality of the 
GPCR under study and the purpose of the study (Figure 6). All the published research on PCAs with 
GPCR dimers involves fusion proteins where the split biosensors are tagged to the C-terminal end of 
GPCRs, so transport and expression at the membrane surface are not hampered. Especially for 
monitoring interactions of Class C GPCRs, like the metabotropic glutamate receptors, C-terminal 
tagging of biosensors is recommended, as modification of the long N-terminus of the receptor could 
lead to deviating outcomes. 
On the other hand, split fragments tagged to the N-termini of GPCRs, though not yet 
implemented for research on GPCR dimerization, might be an interesting tool as well, as these 
fusion proteins may enable the simultaneous monitoring of GPCR-GPCR interactions and the 
signaling properties of the dimer. For example, when a split biosensor is fused to the N-terminus of 
the GPCRs to monitor the GPCR-GPCR interaction, another split biosensor fused to the C-terminus 
of the GPCR can be applied to monitor G-protein or β-arrestin recruitment. 
 
Figure 6. N- or C-terminally split biosensor GPCRs. 
6.1.3. Linkers 
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GPCRs of interest and the fragments of the split luminescent or fluorescent partners are usually 
separated by a linker sequence to assure the flexibility required for the proper folding and “settling” 
of the biosensor. Multiple linkers with alternating sequences and conformations have been designed, 
the design of these linkers often being empirical but based on linker sequences derived from natural 
multi-domain proteins [120]. 
The most frequently applied linkers in PCAs are composed of non-polar glycine and polar 
serine amino acids (“GS” linker), developed by Argos [121]. The flexibility of these linkers originates 
from the incorporation of these small residues. Moreover, the use of serine (or threonine) residues in 
these linkers contributes to the stability in aqueous conditions by the formation of hydrogen bonds 
with water molecules [122]. A model linker design involves the (GGGGS)n template, where n 
represents the copy number. By adjusting this copy number, one might obtain the most optimal 
“GS” linker length to achieve appropriate separation of the GPCR and the split biosensor. For PCA 
purposes, often utilized GS linkers comprise roughly eight to fifteen amino acids, such as 
DGGSGGGS [123], GGGSGGGS [99,124] or GSSGGGGSGGGGSSG [105]. Other -more rigid linkers 
have also been implemented in PCA, for example ATGLDLELKASNSAVDGTAGPVAT [117]. The 
proline residues in linkers might increase stiffness to keep fusion moieties at a distance, whereas 
lysine residues are often added to improve solubility [122]. Furthermore, proper codon usage (i.e., 
avoiding rare ones) is advised to not compromise expression levels. Also, depending on the 
expression system, sequences which could represent potential protease recognition sites should be 
avoided. 
Overall, the selection of the linker length is crucial to allow proper folding and accomplish 
optimal biological activity of the fusion proteins. For fusion proteins, the linker length is an essential 
feature of the PCA setup since linkers that are too short often result in impaired biological activity 
due to the inability to accommodate the complementation of the two split proteins, whereas linkers 
that are too long can create false positives. Therefore, the linker length will vary on a case-by-case 
basis. With this design in mind, the NanoBiT® system offers different restriction sites in the provided 
biosensor templates, resulting in various GS linkers, ranging from 15 to 21 amino acids [112]. Some 
examples of linkers that have been applied in PCA assays to detect GPCR dimers are given in Table 
4. 
Table 4. Linker sequences applied in PCA assays for studying GPCR dimerization. 
GPCR Dimer PCA Type Linker Ref 
AT1−AT2 BiFC, Venus GGGGSGGGG [125] 
CXCR4−CXCR4 BiLC, Rluc (GGGS)2 [99] 
D2LR−D2LR BiFC, Venus LG [100]  
D2LR−D2LR 
A2a−D2R BiLC, Rluc ATGLDLELKASNSAVDGTAGPVAT [117,112] 
D2LR−D2LR BiLC, NanoBiT GNS-GSSGGGGSGGGGSSG [112] 
MOP− NPFF2 BiFC, Venus DGGSGGGS [123] 
6.2. Functionality and Localization of the Fusion Proteins 
Occasionally, the fusion of biosensors to a protein of interest (POI) may interfere with the 
expression level, activity or function of the latter [126,127]. This may, for example, highly depend on 
the sequence and length of the linker between the POI and the biosensor (as discussed in Section 
6.1.). To verify whether the functional integrity of the fusion POI is not affected, several techniques 
should ideally be implemented, such as ligand binding as well as functional assays (e.g., calcium 
signaling, cAMP, β-arrestin recruitment, MAPK activation, etc.). An immunofluorescence assay can 
also be used to confirm correct localization of the recombinant proteins at the plasma membrane. 
6.3. Non-Interacting Partners 
Studying GPCR–GPCR interactions by complementation assays is relatively straightforward. 
However, the importance of including appropriate controls (i.e., GPCRs that do not bind to the 
GPCR of interest) should not be underestimated. It is also essential that the split reporter proteins do 
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not spontaneously associate in the absence of binding partners (that normally drive the 
complementation). If so, a high number of false positives would be generated [112,128,129]. Ideally, 
when the site of interaction is known, a mutation at the specific interaction site of the receptor, is 
performed to evaluate whether this indeed disrupts the interaction. In those cases where the 
interaction site is unknown, a screening could be performed to elucidate the perfect non-interacting 
GPCR partner. Negative controls implemented in already published research articles are shown in 
Table 5 for the BiFC and in Table 6 for BiLC. 
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Table 5. An overview of GPCR–GPCR interactions, shown by fluorescence complementation assays. 
GPCR Dimer Oligomeric Type PCA Split Biosensor Fragments Negative Control Cell-Type Year  Ref. 
In Vivo or 
Native Tissue 
Evidence 
Ref. 
mGluR5−D2R Heterodimer BiFC YFP 1–155, 155–231 GABAB2 HEK 2009 [130] Yes [130] 
D2R−D2R Homodimer BiFC YFP 1–155, 156–238 D1R  HEK 2015 [118] Yes [131,132] 
A2A−D2LR Heterodimer MBiFC Venus/Cerulean 1–172, 155–238 D1 CAD 2008 [59] Yes [130,133–
137] 
D2LR−CB1 Heterodimer MBiFC Venus/Cerulean 1–172, 155–238 M4 CAD 2010 [62] Yes [133] 
D2LR−D2LR Oligomer MBiFC Venus/Cerulean 1–172, 155–238 - CAD 2010 [62] - - 
D2SR−D2SR Homodimer BiFC Venus 1–155, 156–240 CD8 HEK293T 2008 [100] Yes [131,132] 
AT1−AT2 Homo- and 
heterodimer 
BiFC Venus 1–158,159–239 ATIP HEK293FT 2011 [125] Yes 
[138–
140] 
CXCR4−CXCR4 Homodimer BiFC vYFP 1–465, 466–720 D2R HEK293 2014 [99] - - 
A2A−A2A Homodimer MBiFC Venus/Cerulean 1–172, 155–238 - CAD 2008 [59] - - 
A2A−A2A Homodimer BiFC YFP 1–155, 155–238 Non-fused A1 
(competition) 
HEK293T 2018 [65] 
- - 
A2A−A1 Heterodimer BiFC YFP 1–155, 155–238 - HEK293T 2018 [65] Yes [141] 
GHSR1a-OX1R Heterodimer BiFC Venus 1–172, 156–239 - HEK293T 2018 [64] - - 
β2AR−β2AR Oligomer BiFC −15sfGFP  - HeLa 2019 [67] - - 
A2A−A2A  Homodimer BiFC YFP 1–155,156–239 GABAB2 CHO 2018 [66] - - 
A2B−A2A Heterodimer BiFC YFP 1–155,156–239 GABAB2 CHO 2018 [66] - - 
FFAR3−FFAR3 Homodimer BiFC Venus 1–155 (I152L), 155–
239 
P2RY1 HEK293T 2018 [63] 
- - 
FFAR2−FFAR3 Heterodimer BiFC Venus 1–155 (I152L), 155–
238 
P2RY1 HEK293T 2018 [63] 
- - 
mGluR2−mGluR2 Homodimer BiFC mCitrine 1–172, 155–238 - HEK293T 2016 [142] - - 
α1b−α1b Homodimer BiFC eYFP 1–172, 155–238 - HEK293T 2007 [143] - - 
Table 6. An overview of GPCR–GPCR interactions, shown by luminescence complementation assays. 
GPCR Dimer 
Oligomeric 
Type 
PCA 
Type 
Split 
Biosensor 
Fragments 
Negative 
Control 
Cell-Type Year  Ref. 
In vivo or Native Tissue 
Evidence 
Ref. 
CXCR4−CXCR4/CC2 Homodimer 
BiLC FLuc 
NLuc-416 and 
CLuc-398 
β2-AR HEK293T 2009 [98] Yes [144–146] CXCR7−CXCR7 Homodimer 
CXCR4−CXCR7 Heterodimer 
A2a−D2R heterodimer BiLC RLuc8 1–229, 230–311 - HEK293T 2018 [117] Yes [118,130,134–
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137] 
A2a−A2a homodimer BiLC RLuc8 1–229, 230–311 A1 HEK293 2016 [118,101] - - 
D2LR−D2LR homodimer NanoBiT NanoLuc 1–11, 12–167 CB2 HEK293T 2018/2019 [40,112] Yes [131,132] 
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6.4. Normalization Factor 
To allow better comparison between different experimental setups, it is advisable to include a 
normalization factor, i.e., a reporter gene such as a fluorescent marker, as previously described 
[112,147]. In a transient expression system, co-transfection of this fluorescent marker, which should 
not cause cross-excitation, is recommended. A list of PCAs with corresponding fluorescent markers 
is given in Table 7. For BiLC in principle, all fluorescent reporters can be used, although it is 
recommended to avoid cross-excitation by choosing an excitation wavelength more than 20 nm 
before or after the emission wavelength of the luminescent protein. A potential strategy to cope with 
alterations in expression levels of the fusion proteins, is the implementation of ratiometric 
expression systems, consisting of two GPCRs of interest and a fluorescent marker for optical 
expression control. The so-called ratiometric BiFC (rBiFC) makes it feasible to control the expression 
through FACS or flow cytometry analysis [147]. 
Table 7. The application of normalization factors. * Given as examples. 
Fluorescence PCA (Excitation/Emission) Fluorescent Marker (Excitation/Emission) 
 Venus (515/528) CFP (433/475) 
 mCherry (587/610) CFP (433/475)/GFP (488/510)/YFP (514/527) 
 GFP (488/510) CFP (433/475) 
 Cerulean (452/478) mTagBFP (402/457) 
Luminescence PCA Fluorescence Marker 
 Rluc CFP (433/475)/mCherry (587/610) * 
 Fluc CFP (433/475)/mCherry (587/610) * 
 Nluc CFP (433/475)/mCherry (587/610) * 
6.5. Endogenous Expression Levels 
In an arbitrary system, PCAs often involve overexpression of split biosensors since these 
reporter genes are typically introduced in the cells by transfection. To circumvent excessively high 
levels of membrane expression, which may ultimately result in random collisions rather than a real 
interaction, low levels of biosensors should ideally be expressed, preferably close to endogenous 
expression levels. White et al. [148] (2017) have demonstrated that PPIs can be endogenously 
monitored by BRET when a Nanoluciferase reporter is genetically fused to a natively expressed 
GPCR of interest by CRISPR/Cas9-mediated homology-directed repair. This methodology also 
offers the potential to study GPCR–GPCR interactions at endogenous levels. 
6.6. Kinetics 
To follow the dynamics of GPCR interactions in living cells in real time or to monitor the 
influence of ligand-dependent modulation on the level of dimerization, one can use a real-time 
PCA-based method for a certain amount of time. For example, to evaluate the effect of the 
α-melanocyte-stimulating hormone (α-MSH) on the interaction between MC4R and MRAP2, Habara 
et al. [113] (2018) measured this interaction with a NanoBiT®-based PCA for up to 120 s before and 
after the addition of α-MSH. By doing so, the authors could demonstrate that the stimulation of 
MC4R with α-MSH slightly decreased the NanoBiT® signal, which led to the postulation that the 
activated structural change of MC4R negatively impacts the interaction with MRAP2. Overall, 
depending on the half-life of the substrate and the PPI of interest, different timeframes of real-time 
measurement can be implemented. 
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7. HTS with Cell-Based PCAs 
High-throughput screening (HTS) assays are powerful ways to assess the influence of ligands 
that affect the protein complexes, thereby providing a method to measure spatial and temporal 
changes in the protein association in response to drugs (Figure 7). This section will focus on the 
potential use of HTS assays based on BiLC and BiFC for GPCRs. 
7.1. GPCR Oligomerization Screening 
Given that the protein interaction partners are known, PCAs based on BiLC and BiFC could aid 
in studying the strength of the interaction compared to a negative control. To find new (unknown) 
interactions, a screening assay would be handy, in which case the bait protein is fused to a split 
luminescent/fluorescent fragment and screened against a cDNA library fused to the other half of the 
reporter fragment. This way, one can identify which GPCRs interact with each other. In conjunction 
to this is the functional validation of the detected interactions. False readouts can be sidelined upon 
employment of fusion proteins with mutations at the site of interaction, which consequently inhibit 
the interaction and decrease the level of complementation of the luminescent or fluorescent 
fragments. Clearly, this is only feasible if the interaction sites are known, which may be unraveled by 
alanine screening. For such screening assays, a robust plate reader format would be the best choice. 
A non-GPCR example of such a workflow was published by Zych et al. in 2013 [149]. These 
authors established a high-throughput imaging based-screening that was based on the principles of 
BiFC, with as the aim the study of the dynamics of Vpr (a nonstructural protein encoded by HIV-1) 
dimerization. 
Screening based on BiFC coupled to flow cytometry is a fast way to capture weak interactions, 
and hence, this has been used to screen for mutations that modulate the affinity and specificity of 
PPIs. For example, in 2013, Morell et al. [150] coupled flow cytometry to BiFC to study the weak 
interaction between the SH3 domain of C-Abl kinase and its natural or mutated binding partners. 
This combination helps to select for good interacting partners, even if they were deficient in the 
whole cell population. Hence, this combination has proven to be fast, specific, and sensitive and can 
capture even weak, transient interactions, thus opening up a new dimension in the field of 
proteomics. 
7.2. GPCR Drug Discovery 
Since GPCR–GPCR interactions have been implied in several disease patterns, e.g., 
neurodegenerative disorders, a strong interest in compounds which could interfere with or alter 
these GPCR–GPCR interactions has arisen. Monitoring these GPCR–GPCR interactions has the 
potential of unveiling differences in interaction specifics, such as dynamics, as well as identifying 
potential therapeutic agents. 
For an in vitro HTS assay, PCAs can be used to screen for compounds that inhibit (BiLC) or 
enhance (BiLC and BiFC) the PPIs. Upon addition of the modulating compound, the recorded signal 
changes, depending on its potential to influence the GPCR–GPCR interaction. Counter screens 
should be implemented to negate the possibility of an artefact, such as compounds which possibly 
interfere with reporter complementation, show autofluorescence, scatter light, quench luminescence 
or have toxic side-effects [151–153]. A key advantage of PCA-based approaches is that these include 
formats using living cells, so GPCR receptors are in their native environment. 
Overall, this type of HTS strategy would be of great help to further enhance the interest in 
GPCR drug-discovery research. 
Int. J. Mol. Sci. 2019, 20, 2958 24 of 35 
 
 
Figure 7. High-throughput screening. 
8. In Vivo Application 
Besides the potential as HTS assays, in recent years, BiFC and BiLC complementation 
techniques have also been applied in vivo, aiming at a better understanding of the dynamics of 
homo- or heterodimers in living animals. Several studies established an imaging reporter strategy, 
which can monitor the specific pharmacological regulation of oligomer complexes. 
For GPCR dimerization purposes, Luker et al. [98] (2009) applied the FLuc-based PCA 
(NFLuc-416 and CFLuc-398) to investigate the homo- and heterodimerization of CXCR4 and CXCR7 
in a tumor xenograft model of breast cancer. Type 231 cells stably expressing CXCR4-NFLuc and 
CXCR4-CFLuc or CXCR7-NFLuc and CXCR7-CFLuc were injected bilaterally into 6 to 8 weeks-old 
female nude mice. To test whether treatment with chemokine ligands produced time- and 
dose-dependent changes in reporter signal due to the alterations in the level of dimerization, 
fibroblasts stably expressing the chemokine CXCL12 were co-implanted. This chemokine reduced 
the level of both CXCR4 homodimerization and CXCR4−CXCR7 heterodimerization. Blocking the 
binding of CXCL12 to CXCR4 resulted in a time-dependent increase in the level of CXCR4 
homodimer formation, but no increase in the CXCR4−CXCR7 heterodimerization was detected. In 
another setup, mice were injected with 231 cells stably expressing CXCR4 or CXCR7 homodimers 
and with fibroblasts only transduced with GFP. After 1 h of treatment with the CXCR7 modulator 
CCX754 (100 mg/kg subcutaneous), an increase in CXCR7 homodimer formation, but not CXCR4 
homodimer formation, was detected. Overall, it was observed that the chemokine CXCL12 
decreased the level of CXCR4 homodimerization and CXCR4−CXCR7 heterodimerization and the 
CXCR7 modulator CCX754 increased the level of CXCR7 homodimerization. The application of such 
newly designed drugs that specifically modify the levels of certain dimers could be beneficial in the 
treatment of not only breast cancer, but also in rheumatoid arthritis, HIV disease, lung and prostate 
cancers, where these GPCRs play an important role as well. 
Rather than trying to bridge the gap between cell culture studies and in vivo physiology by the 
injection of cells stably expressing GPCRs fused to the split biosensors, use of the CRISPR/Cas9 
methodology (previously described in Section 6.5) to fuse native receptors to split protein fragments 
would allow the detection of dimerization at endogenous protein levels. This has already been 
successfully implemented for the β-arrestin2 recruitment to CXCR4 [148], thus, it could likewise be 
tested for GPCR dimerization. 
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Most importantly, it has been shown that the bioluminescent reporter is sensitive at all the 
depths and locations within a live mouse [154], thus making this one of the best platforms to study 
PPIs as it better mimics a “real-life scenario”. 
In the field of fluorescence, Han et al. [155] in 2014 applied BiFC based on split fragments of 
mNeptune, a far-red monomeric Neptune variant (600 nm/650 nm), for in vivo applications. The 
main obstacle of imaging in live animals, being the tissue opacity to excitation light below 600 nm, 
was overcome by this fluorescent protein. This system was tested by imaging the interaction 
between bFos and bJun in live mice and could also serve to unravel GPCR–GPCR interactions. 
Finally, luminescence- or fluorescence-based systems can be applied to study GPCR 
oligomerization in vivo as these assays allow real-time detection of the interaction and subsequently 
would help in the screening of pharmacological compounds acting on these oligomers. These 
non-invasive animal imaging assays, for the quantification of GPCR–GPCR interactions, might aid 
in the transformation of treatments targeting specific oligomers (e.g., small molecules or bivalent 
ligands) from cell-based assays to clinical trials. 
9. Conclusion 
GPCRs are highly dynamic proteins that are subject to multiple spatiotemporal interactions 
inside the cell to trigger appropriate cellular responses. These interactions involve transducers, 
kinases, as well as other GPCRs, among others [156–158]. While great progress has been made 
during the past decade in targeting and understanding GPCR–GPCR interactions, some key 
questions remain unanswered. Although increasing evidence supports the existence of GPCR–
GPCR interactions in vitro and in vivo [159], the sophisticated characteristics of these interactions, 
such as their variation in dynamics, complexity (i.e., dimerization or higher-order oligomerization), 
binding affinities, and the lack of a consensus sequence in the interfaces, make GPCR–GPCR 
interactions a challenging research field. Multiple studies based on PCA techniques have shed new 
light on the composition, localization, and even ligand-induced modulation of these GPCR 
complexes. Moreover, the potential of these PCA-based methodologies has been further explored by 
their combination in a variety of ways to investigate not only binary but also ternary or even 
quaternary partnerships. The current review describes the journey taken by these BiLC- and 
BiFC-based PCAs and the GPCR–GPCR interactions that have been identified by applying these 
techniques. PCAs are straightforward and flexible, and provide on the one hand a convenient 
approach to visualize the oligomerization processes in living cells and on the other hand an ideal 
tool to monitor the interaction dynamics. Nevertheless, certain milestones could still be achieved, 
such as the development of reversible split-fluorescent proteins or the discovery of split-luminescent 
proteins and their respective ligands that allow enhanced imaging of the GPCR–GPCR interactions. 
Finally, we anticipate a growing interest in the application of PCA-based high-throughput drug 
screenings, which makes it possible to identify compounds that selectively modulate the 
composition of GPCR oligomers in living cells. 
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Abbreviations 
A1/A2A Adenosine receptor type 1/type 2A 
α1b α1b adrenergic receptor 
AT1/AT2 Angiotensin II receptor type 1/type 2 
β2AR β2 Adrenergic receptor 
BiFC Bimolecular fluorescence complementation assay 
BiLC Bimolecular luminescence complementation assay 
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BRET Bioluminescence resonance energy transfer 
CAD Cath.-a-differentiated 
cAMP Cyclic adenosine monophosphate 
CB1 Cannabinoid receptor 1 
CC C-terminal fragment of split Cerulean 
CFP Cerulean fluorescent protein 
CC2 C-C chemokine receptor type 2 
CFLuc C-terminal fragment of split Firefly luciferase 
CGFP C-terminal fragment of split green fluorescent protein 
CID Chemically induced dimerization 
CN N-terminal fragment of split Cerulean 
CODA-RET Complemented donor–acceptor resonance energy transfer 
co-IP Co-immunoprecipitation 
CPA N6-cyclopentyladenosine 
CXCR4/CXCR7 C-X-C chemokine receptor type 4/type 7 
D1R/D2R/D3R Dopamine receptor type 1/type 2/type 3 
D2LR Dopamine receptor type 2 long isoform 
D2SR Dopamine receptor type 2 short isoform 
DsRed Discosoma Red 
ECL Extracellular loop 
EGFP Enhanced green fluorescent protein 
FLuc Firefly Luciferase 
FFAR2/3 Free fatty acid receptor type 2/type 3 
FRB FKBP-rapamycin binding domain of mTOR 
FKBP12 FK506- and rapamycin-binding protein 
FRET Förster resonance energy transfer 
GHSR1a Growth hormone secretagogue receptor 1α 
GLuc Gaussia princeps luciferase 
GPCR G protein-coupled receptor 
GRK G protein-coupled receptor kinase 
HEK Human embryonic kidney 
Homo-FC Homo-molecular fluorescence complementation 
5-HTR 5-hydroxytryptamine receptor 
HTS High-throughput screening 
L-DOPA L-3,4-dihydroxyphenylalanine 
LcBiT C-terminal fragment of split large BiT 
LgBiT Large BiT, large subunit of Nanoluciferase 
LnBiT N-terminal fragment of split large BiT 
M1/M2/M4 Muscarinic acetylcholine receptor type 1/type 2/type 4 
MAPK Mitogen activated protein kinase 
MBiFC Multicolor Bimolecular fluorescence complementation assay 
MC4R Melanocortin 4 receptor 
MOP Mu-opioid receptor 
MRAP2 Melanocortin 2 receptor accessory protein 2 
α-MSH α-Melanocyte- stimulating hormone 
mGluR2/mGLuR5/mGluR6 Metabotropic glutamate receptor type 2/type 5/type 6 
mRFP Monomer red fluorescent protein 
NanoBiT® NanoLuc Binary Technology® 
NFLuc N-terminal fragment of split Firefly luciferase 
NGFP N-terminal fragment of split green fluorescent protein 
NPFF2 Neuropeptide FF receptor 2 
NPY Neuropeptide Y 
OX1R Orexin 1 receptor 
PCA Protein complementation assay 
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PLA Proximity ligation assay 
PPI Protein–protein interaction 
P2RY1 P2Y purinoceptor 1 
RLuc Renilla Luciferase 
SDS-PAGE Sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
SH3 SRC Homology 3 Domain 
SmBiT Small BiT, small subunit of Nanoluciferase 
SpIDA Spatial intensity distribution analysis 
SRET Sequential resonance energy transfer 
TAT Transactivator of transcription  
TM Transmembrane 
TSHr Thyrotropin receptor 
VC C-terminal fragment of split Venus 
VN N-terminal fragment of split Venus 
YC C-terminal fragment of split yellow fluorescent protein 
YFP Yellow fluorescent protein 
YN N-terminal fragment of split yellow fluorescent protein 
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